Pete Knox

Home/Pete Knox

About Pete Knox

This author has not yet filled in any details.
So far Pete Knox has created 27 blog entries.

Stepping into Personalized Side Effect Management with SideEQ

What Can SideEQ Do for You? What is personalized side effect management, and why is it important for your survival and quality of life? “Never judge a person until you’ve walked a mile in [...]

By |2019-06-20T11:37:27-05:00June 20th, 2019|News, Newsletter, Side Effects|

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By |2018-10-30T09:41:06-05:00July 19th, 2016|Clinical Trials, News, Research|

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2018-10-30T09:42:39-05:00July 12th, 2016|Clinical Trials, News, Research|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By |2019-07-03T10:45:21-05:00May 24th, 2016|Clinical Trials, News, Research|

Genetic Alliance Event Invites Collaboration

Genetic Alliance recently held an event in Chapel Hill, N.C. that brought together patient advocates, scientists and representatives from the pharmaceutical industry in a unique “speed-dating” format. Disease advocacy organizations were invited to present briefly [...]

By |2018-10-30T11:28:10-05:00December 16th, 2015|Advocacy, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-05:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|